secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-10-01T23:35:44+00:00
Accession:  0001193125-26-411011
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Cullinan starts FDA NDA submission for zipalertinib combo in 1L EGFR ex20ins NSCLC under RTOR
--------------------------------------------------------------------------------

- NDA submission initiated for zipalertinib plus platinum-based chemotherapy in previously untreated, locally advanced or metastatic EGFR exon 20 insertion NSCLC.
- Submission is under the FDA's Real-Time Oncology Review program; completion of the NDA submission expected by year-end 2026.
- Based on Phase 3 REZILIENT3, which met its primary endpoint with a statistically significant improvement in median PFS vs chemotherapy alone; data presented at IASLC 2026 WCLC Presidential Symposium.
- A separate NDA seeking accelerated approval for zipalertinib monotherapy in second-line EGFR ex20ins NSCLC remains under FDA review, with a PDUFA target action date of February 27, 2027.
- Cullinan is eligible for $30.0 million and up to $100.0 million in Taiho milestone payments upon U.S. second-line and first-line approvals, respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526411011/0001193125-26-411011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526411011/cgem-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-411011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer